Little interest from pharma in US FDA's drug naming pilot programme
This article was originally published in SRA
Executive Summary
A two-year, US Food and Drug Administration pilot programme to find the best model for evaluating proposed proprietary names for medicines has drawn a poor response from the pharmaceutical industry1-3.